ClinicalTrials.gov Identifier: NCT01327846.
“Nonetheless, an exploratory CANTOS genomic substudy revealed a 62% major adverse cardiovascular event (MACE) reduction with canakinumab (HR, 0.38; 95% CI, 0.15-0.96) in patients with TET2 clonal hematopoiesis of indeterminate potential (CHIP).”
Svensson et al. (2022) studied this question.